Search results
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 6 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
EMA CHMP recommends AstraZeneca’s Tagrisso for lung cancer
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
3 No-Brainer Stocks to Buy in June | The Motley Fool
The Motley Fool· 5 days agoYou're probably familiar with the old adage, "April showers bring May flowers." Here's why they picked AbbVie (ABBV 3.15%), AstraZeneca (AZN 1.63%), and...
ASCO24: Tagrisso in the spotlight, Caribou’s adjustment and Lilly’s KRAS competitor
BioPharma Dive via Yahoo Finance· 3 days agoAstraZeneca’s therapy could see wider use after ASCO data. Elsewhere, Caribou sought to explain an...
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 5 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 5 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 5 days agoBut what does June bring? Three Motley Fool contributors think the new month should usher in great investing opportunities. Here's why they picked AbbVie...
Women denied ‘wonder drug’ that could double terminal breast cancer life expectancy
Daily Telegraph· 3 days agoWomen with HER2-low or ultra-low breast cancer who took Enhertu lived without their cancer growing...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 7 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
Veeva R&D Summit: Pharma companies need a say in AI regulation
Clinical Trials Arena via Yahoo Finance· 15 hours agoSenderovitz is working with partners from other pharmaceutical companies, including James...